# Pear Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pear-therapeutics

- Industry: Healthcare IT
- Headquarters: Boston, US
- Website: www.peartherapeutics.com
- Total disclosed funding: $203M
- Latest round: Series D (Dec 7, 2020)
- Investors on record: 16

## About

Founded in 2013 and based in Massachusetts, US, Pear Therapeutics, Inc. provides an end-to-end platform for Prescription Digital Therapeutics (PDTs) that allows patients to connect and engage with physicians through its mobile application. The company was co-founded by the CEO Corey McCann, alongside Stephen Smith and William Greene. 

In 2020, Pear Therapeutics, Inc. raised USD 80 million in Series D funding, as a part of a larger USD 100 million Series D funding round, led by new investor SB Investment Advisers. In 2021, Pear Therapeutics, Inc. entered into a business combination agreement with Thimble Point Acquisition Corp. The transaction is valued at USD 125 million, at USD 10 per share.

The company offers software-based disease treatment solutions that focus on specific areas such as reSET® – intended for substance use disorder, reSET-O® – for opioid use disorder, Somryst® – treatment for chronic insomnia, PEAR-004 – for schizophrenia, and PEAR-006 – for multiple sclerosis. Pear Therapeutics, Inc. also provides PearConnect, a patient service center used for Prescription Digital Therapeutics (or PDTs).

The company generates revenue by selling software-based solutions to healthcare institutions.

Following the funding in 2020, Pear Therapeutics, Inc. plans to use the investment to develop and commercialize the three commercial products under clinical trial. Post the closing of its business combination with Thimble, the company plans to list on the Nasdaq under the new ticker symbol, PEAR and will be renamed as Pear Holdings Corp.

## Funding rounds

- Series D, Dec 7, 2020, $80M — 5AM Ventures, Arboretum Ventures, SG Growth Capital, Temasek Holdings, Pilot House Ventures, Shanda Capital, Sarissa Capital Management, Novartis, QUAD Investment Management, JAZZ Venture Partners, SB Investment Advisers, CrimsoNox Capital, Forth Management, LLC
- Series C, Dec 21, 2018, $64M — Temasek Holdings, 5AM Ventures, Arboretum Ventures, SG Growth Capital, Trustbridge Partners, Novartis, JAZZ Venture Partners, Bridge Builders Collaborative, Blue Water Life Science Fund
- Series B, Dec 28, 2017, $46M — Temasek Holdings, 5AM Ventures, Arboretum Ventures, SG Growth Capital, Novartis, JAZZ Venture Partners, Bridge Builders Collaborative
- Series A, Jan 26, 2016, $12M — 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Bridge Builders Collaborative

## Investors

- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A, Series B, Series C, Series D
- Arboretum Ventures (https://capitalatlas.ai/funds/arboretum-ventures) — Series A, Series B, Series C, Series D
- JAZZ Venture Partners (https://capitalatlas.ai/funds/jazz-venture-partners) — Series A, Series B, Series C, Series D
- Bridge Builders Collaborative (https://capitalatlas.ai/funds/bridge-builders-collaborative) — Series A, Series B, Series C
- Temasek Holdings — Series B, Series C, Series D
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series B, Series C, Series D
- Novartis — Series B, Series C, Series D
- Trustbridge Partners (https://capitalatlas.ai/funds/trustbridge-partners) — Series C
- Blue Water Life Science Fund — Series C
- Pilot House Ventures (https://capitalatlas.ai/funds/pilot-house-ventures) — Series D
- Shanda Capital — Series D
- Sarissa Capital Management — Series D
- QUAD Investment Management (https://capitalatlas.ai/funds/quad-investment-management) — Series D
- SB Investment Advisers (https://capitalatlas.ai/funds/sb-investment-advisers) — Series D
- CrimsoNox Capital — Series D
- Forth Management, LLC — Series D